4Q24 consolidated revenue came in at W496.1bn (+13.5% YoY), with operating loss of W19.0bn (swing to loss). R&D expenses surge by 93% on new pipeline introduction and clinical trial initiation
What is covered in the Full Insight:
Introduction
4Q24 Financial Performance Review
R&D and Pipeline Developments
2025 Earnings Outlook
Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.